The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
The Roles of CD8+ T Cell Subsets in Antitumor Immunity
Abstract
Effector CD8+ T cells are typically thought to be a homogenous group of cytotoxic cells that produce interferon-(IFN) γ. However, recent findings have challenged this notion because multiple subsets of CD8+ T cells have been described, each with distinct effector functions and cytotoxic potential. These subsets, referred to as the Tc subsets, have also been detected in tumor microenvironments (TMEs), where they potentially influence the antitumor response and patient outcomes. In this review, we highlight the prevalence and roles of Tc subsets in the TME. We also discuss their therapeutic applications in the context of adoptive immunotherapy to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Differing Lymphokine Profiles of Functional Subsets of Human CD4 and CD8 T Cell Clones
Salgame, P., Abrams, J. S., Clayberger, C., Goldstein, H., Convit, J., Modlin, R. L., & Bloom, B. R. (1991) · Science · doi:10.1126/science.1681588 · Cited by 1,028
Control of Effector CD8 + T Cell Function by the Transcription Factor Eomesodermin
Pearce, E. L., Mullen, A. C., Martins, G. A., Krawczyk, C. M., Hutchins, A. S., Zediak, V. P., Banica, M., DiCioccio, C. B., Gross, D. A., Mao, C.-A., et al. (2003) · Science · doi:10.1126/science.1090148 · Cited by 1,014
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Commensal–dendritic-cell interaction specifies a unique protective skin immune signature
Naik, S., Bouladoux, N., Linehan, J. L., Han, S.-J., Harrison, O. J., Wilhelm, C., Conlan, S., Himmelfarb, S., Byrd, A. L., Deming, C., et al. (2015) · Nature · doi:10.1038/nature14052 · Cited by 820
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Goc, J., Germain, C., Vo-Bourgais, T. K. D., Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, E., Alifano, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1342 · Cited by 677
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Nograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
Croft, M., Carter, L., Swain, S. L., & Dutton, R. W. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1715 · Cited by 514
Non-classical Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair
Linehan, J. L., Harrison, O. J., Han, S.-J., Byrd, A. L., Vujkovic-Cvijin, I., Villarino, A. V., Sen, S. K., Shaik, J., Smelkinson, M., Tamoutounour, S., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.033 · Cited by 456
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., Chang, A., & Zou, W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6730 · Cited by 416
Anomalous Type 17 Response to Viral Infection by CD8 + T Cells Lacking T-bet and Eomesodermin
Intlekofer, A. M., Banerjee, A., Takemoto, N., Gordon, S. M., DeJong, C. S., Shin, H., Hunter, C. A., Wherry, E. J., Lindsten, T., & Reiner, S. L. (2008) · Science · doi:10.1126/science.1159806 · Cited by 394
Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR6
Singh, S. P., Zhang, H. H., Foley, J. F., Hedrick, M. N., & Farber, J. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.214 · Cited by 371
GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells
Pai, S.-Y., Truitt, M. L., & Ho, I.-C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308697100 · Cited by 349
He, D., Li, H., Yusuf, N., Elmets, C. A., Li, J., Mountz, J. D., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902574 · Cited by 334
Res, P. C. M., Piskin, G., de Boer, O. J., van der Loos, C. M., Teeling, P., Bos, J. D., & Teunissen, M. B. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014108 · Cited by 328
Heterogeneity in the Differentiation and Function of CD8+ T Cells
Mittrücker, H.-W., Visekruna, A., & Huber, M. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0293-y · Cited by 325
Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 production
Fujita, H., Nograles, K. E., Kikuchi, T., Gonzalez, J., Carucci, J. A., & Krueger, J. G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911472106 · Cited by 254
IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis
Huber, M., Heink, S., Pagenstecher, A., Reinhard, K., Ritter, J., Visekruna, A., Guralnik, A., Bollig, N., Jeltsch, K., Heinemann, C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63681 · Cited by 254
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors
Thompson, E. D., Enriquez, H. L., Fu, Y.-X., & Engelhard, V. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092454 · Cited by 249
A Th17‐like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity
Huber, M., Heink, S., Grothe, H., Guralnik, A., Reinhard, K., Elflein, K., Hünig, T., Mittrücker, H., Brüstle, A., Kamradt, T., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200939412 · Cited by 229
Type 17 CD8+ T cells display enhanced antitumor immunity
Hinrichs, C. S., Kaiser, A., Paulos, C. M., Cassard, L., Sanchez-Perez, L., Heemskerk, B., Wrzesinski, C., Borman, Z. A., Muranski, P., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-02-203935 · Cited by 225
CD8+ T cells can be primed in vitro to produce IL-4
Seder, R. A., Boulay, J. L., Finkelman, F., Barbier, S., Ben-Sasson, S. Z., Le Gros, G., & Paul, W. E. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.6.1652 · Cited by 208
Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer
Sheu, B.-C., Lin, R.-H., Lien, H.-C., Ho, H.-N., Hsu, S.-M., & Huang, S.-C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2972 · Cited by 205
Huber, S., Hoffmann, R., Muskens, F., & Voehringer, D. (2010) · Blood · doi:10.1182/blood-2010-02-271981 · Cited by 204
Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity
Yen, H.-R., Harris, T. J., Wada, S., Grosso, J. F., Getnet, D., Goldberg, M. V., Liang, K.-L., Bruno, T. C., Pyle, K. J., Chan, S.-L., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900368 · Cited by 194
Benevides, L., da Fonseca, D. M., Donate, P. B., Tiezzi, D. G., De Carvalho, D. D., de Andrade, J. M., Martins, G. A., & Silva, J. S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0054 · Cited by 182
Zhuang, Y., Peng, L., Zhao, Y., Shi, Y., Mao, X., Chen, W., Pang, K. C., Liu, X., Liu, T., Zhang, J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.010 · Cited by 168
Cholesterol negatively regulates IL-9–producing CD8+ T cell differentiation and antitumor activity
Ma, X., Bi, E., Huang, C., Lu, Y., Xue, G., Guo, X., Wang, A., Yang, M., Qian, J., Dong, C., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171576 · Cited by 165
Karyampudi, L., Lamichhane, P., Scheid, A. D., Kalli, K. R., Shreeder, B., Krempski, J. W., Behrens, M. D., & Knutson, K. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2564 · Cited by 162
Kuang, D., Peng, C., Zhao, Q., Wu, Y., Zhu, L., Wang, J., Yin, X., Li, L., & Zheng, L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904094 · Cited by 160
Patil, R. S., Shah, S. U., Shrikhande, S. V., Goel, M., Dikshit, R. P., & Chiplunkar, S. V. (2016) · International Journal of Cancer · doi:10.1002/ijc.30134 · Cited by 159
Lu, Y., Hong, B., Li, H., Zheng, Y., Zhang, M., Wang, S., Qian, J., & Yi, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317431111 · Cited by 146
Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity
Kemp, R. A., & Ronchese, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6497 · Cited by 146
Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6
Liu, S., Tsai, J.-P., Shen, C., Sher, Y., Hsieh, C.-L., Yeh, Y.-C., Chou, A., Chang, S.-R., Hsiao, K.-N., Yu, F.-W., et al. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0207111 · Cited by 128
García-Hernández, M. D. L. L., Hamada, H., Reome, J. B., Misra, S. K., Tighe, M. P., & Dutton, R. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902995 · Cited by 124
Gartlan, K. H., Markey, K. A., Varelias, A., Bunting, M. D., Koyama, M., Kuns, R. D., Raffelt, N. C., Olver, S. D., Lineburg, K. E., Cheong, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-622662 · Cited by 116
Recent advances in CD8+ regulatory T�cell research (Review)
Yu, Y., Ma, X., 宫汝飞, Zhu, J., Wei, L., & Yao, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8378 · Cited by 113
Nanjappa, S. G., Héninger, E., Wüthrich, M., Gasper, D. J., & Klein, B. S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002771 · Cited by 111
Understanding memory CD8 + T cells
Samji, T., & Khanna, K. M. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.012 · Cited by 105
Circulatory Antigen Processing by Mucosal Dendritic Cells Controls CD8+ T Cell Activation
Chang, S. Y., Song, J.-H., Guleng, B., Alonso, C., Arihiro, S., Zhao, Y., Chiang, H.-S., O’Keeffe, M. S., Liao, G., Karp, C. L., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.018 · Cited by 104
A Portrait of CXCR5+ Follicular Cytotoxic CD8+ T cells
Yu, D., & Ye, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.002 · Cited by 99
Ito, N., Nakamura, H., Tanaka, Y., & Ohgi, S. (1999) · Cancer · Cited by 97
Zhang, S., Fujita, H., Mitsui, H., Yanofsky, V. R., Fuentes‐Duculan, J., Pettersen, J. S., Suárez‐Fariñas, M., Gonzalez, J., Wang, C. Q. F., Krueger, J. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062154 · Cited by 96
Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNγ/Stat1 signals
Yang, Y., Ochando, J., Bromberg, J. S., & Ding, Y. (2007) · Blood · doi:10.1182/blood-2006-11-058271 · Cited by 96
Tc9 cells, a new subset of CD8+ T cells, support Th2‐mediated airway inflammation
Visekruna, A., Ritter, J., Scholz, T., Campos, L., Guralnik, A., Poncette, L., Raifer, H., Hagner, S., Garn, H., Staudt, V., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242825 · Cited by 95
Nishimura, F., Dusak, J. E., Eguchi, J., Zhu, X., Gambotto, A. A., Storkus, W. J., & Okada, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3825 · Cited by 94
McDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R., Currie, A. J., & Robinson, B. W. S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444722 · Cited by 91
Chan, W. L., Pejnovic, N. N., Lee, C. A., & Al-Ali, N. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1238 · Cited by 89
IL-9 and Th9 cells: progress and challenges
Zhao, P., Xiao, X., Ghobrial, R. M., & Li, X. C. (2013) · International Immunology · doi:10.1093/intimm/dxt039 · Cited by 85
Dobrzanski, M. J., Reome, J. B., & Dutton, R. W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.916 · Cited by 85
Tajima, M., Wakita, D., Satoh, T., Kitamura, H., & Nishimura, T. (2011) · International Immunology · doi:10.1093/intimm/dxr086 · Cited by 80
Hilvering, B., Hinks, T., Stoeger, L., Marchi, E., Salimi, M., Shrimanker, R., Liu, W., Chen, W., Luo, J. F., Go, S., et al. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0049-9 · Cited by 75
Lee, M.-H., Chang, J. T., Liao, C., Chen, Y.-S., Kuo, M., & Shen, C. (2018) · Oncotarget · doi:10.18632/oncotarget.23934 · Cited by 57
Endogenously Produced IL-4 Nonredundantly Stimulates CD8+ T Cell Proliferation
Morris, S. C., Heidorn, S. M., Herbert, D. R., Perkins, C. L., Hildeman, D. A., Khodoun, M. V., & Finkelman, F. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1429 · Cited by 53
Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer
Reome, J. B., Hylind, J. C., Dutton, R. W., & Dobrzanski, M. J. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.11.013 · Cited by 53
Ito, N., Suzuki, Y., Taniguchi, Y., Ishiguro, K., Nakamura, H., & Ohgi, S. (2005) · PubMed · Cited by 51
IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function
Paul, M. S., Saibil, S. D., Lien, S. C., Han, S., Sayad, A., Mulder, D. T., Garcia-Batres, C. R., Elford, A. R., Israni-Winger, K., Robert-Tissot, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0521 · Cited by 50
Self-citationLangerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity
Fujita, H., Suárez‐Fariñas, M., Mitsui, H., Gonzalez, J., Bluth, M. J., Zhang, S., Felsen, D., Krueger, J. G., & Carucci, J. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.34 · Cited by 49
Dobrzanski, M. J., Reome, J. B., Hylind, J. C., & Rewers‐Felkins, K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8191 · Cited by 45
Nanjappa, S. G., McDermott, A. J., Fites, J. S., Galles, K., Wüthrich, M., Deepe, G. S., & Klein, B. S. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006356 · Cited by 45
Furlan, S. N., Watkins, B. K., Tkachev, V., Cooley, S., Panoskaltsis‐Mortari, A., Betz, K., Brown, M., Hunt, D. J., Schell, J. B., Zeleski, K., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726547 · Cited by 41
Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Hylind, J. C., & Dutton, R. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2580 · Cited by 39
Chellappa, S., Hugenschmidt, H., Hagness, M., Subramani, S., Melum, E., Line, P., Labori, K. J., Wiedswang, G., Taskén, K., & Aandahl, E. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600061 · Cited by 39
CD 73‐mediated adenosine production promotes stem cell‐like properties in mouse Tc17 cells
Flores‐Santibáñez, F., Fernández, D., Meza, D., Tejón, G., Vargas, L., Varela‐Nallar, L., Arredondo, S. B., Guixé, V., Rosemblatt, M. S., Bono, M. R., et al. (2015) · Immunology · doi:10.1111/imm.12529 · Cited by 34
Wang, X.-F., Zhu, Y., Wang, J., Zeng, D., Mu, C., Chen, Y., Lei, W., Zhu, Y., & Huang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185168 · Cited by 30
Flores‐Santibáñez, F., Cuadra, B., Fernández, D., Rosemblatt, M. V., Núñez, S., Cruz, P., Gálvez‐Cancino, F., Cárdenas, C., Lladser, Á., Rosemblatt, M. S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00209 · Cited by 28
Bowers, J. S., Nelson, M. H., Kundimi, S., Bailey, S. R., Huff, L. W., Schwartz, K. M., Cole, D. J., Rubinstein, M. P., & Paulos, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2294 · Cited by 27
Faghih, Z., Rezaeifard, S., Safaei, A., Ghaderi, A. A., & Erfani, N. (2013) · PubMed · doi:10.22034/iji.2013.16836 · Cited by 25
Wang, S., Li, Z., & Hu, G. (2017) · Oncotarget · doi:10.18632/oncotarget.18807 · Cited by 22
Committed Tc17 cells are phenotypically and functionally resistant to the effects of IL‐27
Behi, M. E., Dai, H., Magalhaes, J. G., Hwang, D. H., Zhang, G., Rostami, A. M., & Ćirić, B. (2014) · European Journal of Immunology · doi:10.1002/eji.201344360 · Cited by 20
Anichini, A., Mortarini, R., Romagnoli, L., Baldassari, P., Cabras, A. D., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2005) · Blood · doi:10.1182/blood-2005-06-2234 · Cited by 18
Saito, H., Yamada, Y., Takaya, S., Osaki, T., & Ikeguchi, M. (2015) · Surgery Today · doi:10.1007/s00595-015-1165-8 · Cited by 16
Wang, W., Cheng, Z., Chen, Y., & Lin, Y.-H. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3870 · Cited by 12
Cited by
Pan-cancer single-cell landscape of tumor-infiltrating T cells
Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402
Hezaveh, K., Shinde, R. S., Klötgen, A., Halaby, M. J., Lamorte, S., Ciudad, M. T., Quevedo, R., Neufeld, L., Liu, Z. Q., Jin, R., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.006 · Cited by 746
Self-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Metadata
- Authors
- St. Paul, M., & Ohashi, P. S.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 30
- Issue
- 9
- Pages
- 695-704
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W3039693333
- Cited by
- 609
- References
- 84
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.